

TriMark Publications

January 2015  
Volume: TMRIVD15-0101

# IN VITRO DIAGNOSTIC TESTING WORLD MARKETS

*(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers

**TABLE OF CONTENTS**

1.	IVD Market Overview	14
1.1	Statement of Report	14
1.2	About This Report	14
1.3	Scope of the Report	14
1.4	Objectives	15
1.5	Methodology	15
1.6	Executive Summary	16
2.	IVD Global Market Overview	19
2.1	Total Global IVD Market	19
2.2	International Sector and Country IVD Markets	20
2.3	IVD Market Segments by Analyte	23
2.4	High Growth Markets	24
2.4.1	Summary Analysis of the Global IVD High-Growth Market by Geographic Region	24
2.4.1.1	U.S.: Summary of IVD High-Growth Market	25
2.4.1.2	Europe: Summary Analysis of the IVD High-Growth Market	26
2.4.1.3	South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market	28
2.4.1.4	BRIC: Summary Analysis of the IVD High-Growth Market	29
2.4.1.4.1	Brazil: Summary Analysis of the IVD High-Growth Market	29
2.4.1.4.2	Russia: Summary Analysis of the IVD High-Growth Market	30
2.4.1.4.3	Indian IVD High Growth Markets	31
2.4.1.4.4	Summary of IVD High-Growth Market India	33
2.4.1.4.5	China: Summary Analysis of the IVD High-Growth Market	34
2.4.1.4.6	Summary of IVD High-Growth Market China	36
2.5	Key Players	37
2.6	Key Trends in the IVD Industry	38
2.7	Acquisitions	38
2.8	Market Drivers and Barriers	42
2.8.1	Key Market Drivers	42
2.8.2	Barriers to Growth	43
2.9	Companion Diagnostics	43
3.	POCT	46
3.1	POCT Market Overview	46
3.1.1	Total Global POCT Market	47
3.1.2	International Sector and Country POCT Markets	47
3.2	POCT Market Segments by Analyte	48
3.3	Key Players	50
3.3.1	Acquisition, License Agreements, Internal Development and Partnerships	51
3.4	Key Concepts for POCT Markets	52
3.5	The Future of POCT	54
3.6	The Biggest New Opportunities in POCT	55
4.	Molecular Diagnostics	56
4.1	Market Overview	56
4.2	Market Size and Growth Rate	57
4.3	Key Players	58
4.4	Market Segments	59
4.4.1	Infectious Disease	60
4.4.1.1	Key Segments of Molecular Diagnostic Markets for Infectious Disease	61
4.4.2	Cancer	66
4.4.2.1	Technology and Market Trends in Cancer Testing	67
4.4.2.2	Cancer Testing	69
4.4.2.3	Cancer Prognostic Assays	72

4.4.2.4	Market Size	72
4.4.2.5	Key Players	74
4.4.2.6	Competitive Landscape	74
4.4.2.6.1	Myriad Genetics (BRCA1 and BRCA2)	75
4.4.2.6.2	Genomic Health (Oncotype DX)	76
4.4.2.6.3	InterGenetics, Inc.	77
4.4.2.6.4	Clariant, Inc. (GE Healthcare)	78
4.4.2.6.5	BioTheronostics	78
4.4.2.6.6	Agendia B.V. (MammaPrint)	79
4.4.2.6.7	LabCorp	80
4.4.2.6.8	Quest Diagnostics	81
4.4.2.7	Competitive Structure and Market Share Analysis	81
4.4.2.8	Drivers and Restraints	82
4.4.2.8.1	Molecular Diagnostics Cancer Market Drivers Ranked in Order of Impact	82
4.4.2.8.2	Molecular Diagnostics Cancer Market Restraints Ranked in Order of Impact	82
4.4.2.9	Business Factors Influencing Advanced Oncology Testing Services	82
4.4.2.10	Market Trends in Cancer Testing	83
4.4.2.11	Strategic Recommendations on Molecular Diagnostic Sector Business Functions	83
4.4.2.12	Emerging Cancer Personalized Medicine Market	83
4.4.3	Genetic Testing	84
4.4.3.1	Genetic Testing Market	84
4.4.3.2	Primary Competitors	86
4.4.3.3	Prominent Issues in Genetic Prenatal Diagnosis Using Molecular Diagnostics Testing	86
4.5	Snapshot of Molecular Diagnostics Industry Structure	87
4.5.1	Technology and Market Trends	88
4.5.2	Emerging Technologies	89
4.5.3	Market Trends	89
4.6	Molecular Diagnostics Testing Going Forward	91
4.7	Key Sector Takeaways	93
5.	Clinical Chemistry	94
5.1	Market Overview	94
5.2	International Markets	95
5.2.1	U.S. Market	95
5.2.2	European Market	95
5.2.3	Asian Market	96
5.3	Key Players	97
5.4	Market Segments	97
5.4.1	Ultra-Large Throughput Chemistry Analyzers	99
5.4.2	Large Throughput Analyzers	100
5.4.3	Mid-Size Clinical Chemistry Analyzers	101
5.4.4	Chemistry Analyzers for the Small-Volume Market	103
5.5	Long-Term Changes	104
5.6	Market Drivers	105
5.7	The Limits to Growth	106
5.8	Hot Sectors in the IVD Market	107
5.9	Key Technologies	107
5.10	Key Sector Takeaways	108
6.	Diabetes and Glucose Testing	109
6.1	Market Overview	109
6.2	Glucose Self-Testing Markets	111
6.3	Key Players	114
6.3.1	M&A Activity	115
6.3.2	Important Deals in BGM Market	115
6.4	Future of Patient Self-testing	116

6.5	Lancet Market	117
6.5.1	Market Size	117
6.5.2	Strategic Recommendations in the Lancet Business	119
6.5.3	Health and Safety Regulations	120
6.5.4	Key Players in the Blood Lancet Market	121
6.5.5	Lancet Distribution Networks	122
6.6	Drivers of OTC and Self-testing Markets	122
6.6.1	Factors Affecting OTC Medical Product Distribution	122
6.6.2	Drugstores Critical to the Diabetic Care Category	124
6.7	Important Elements of OTC Testing	124
6.8	Strategic Recommendations for Self-Monitoring Blood Glucose Markets	125
6.9	Future of Patient Self-Testing	125
7.	Immunochemistry Markets	126
7.1	Market Overview	126
7.2	Markets for Immunoanalyzer Testing	126
7.3	Key Players	127
7.3.1	Abbott Diagnostics	127
7.3.2	Siemens	128
7.3.3	Roche	129
7.3.4	Beckman Coulter, Inc.	130
7.3.5	bioMérieux	131
7.3.6	Ortho-Clinical Diagnostics	132
7.4	Long Term Changes	133
7.4.1	Key Developments	133
7.5	Market Drivers and Restraints	134
7.6	Hot Sectors in the Immunoanalyzer Market	136
7.7	Key Technologies	137
7.7.1	Analyzer Integration Chemistry/Immunoassay	138
7.7.2	Consolidated Workstations	139
7.8	Key Sector Takeaways	140
8.	Hematology	142
8.1	Market Overview	142
8.2	International Markets	142
8.2.1	U.S. Market	143
8.2.2	European Market	143
8.2.3	Asian Market	143
8.3	Key Players	143
8.4	Hematology Analyzers	144
8.4.1	Large Throughput Analyzers	145
8.4.2	Mid-Size Analyzers	145
8.4.3	Analyzers for the Small Volume Market	146
8.4.4	New Hematology Analyzers	147
8.5	Profitability	147
8.6	Market Drivers	147
8.7	Key Sector Takeaways	148
9.	Coagulation	149
9.1	Market Overview	149
9.2	International Markets	150
9.2.1	U.S. Market	150
9.2.2	European Market	151
9.2.3	Asian Market	151
9.2.4	Rest of the World Markets	152
9.3	Key Players	153

9.4	Recent Coagulation Testing Sector Activity	155
9.4.1	Roche and Diagnostica Stago Parting Ways in Laboratory Coagulation	155
9.4.2	Roche Acquires Verum Diagnostica GmbH and Expands Coagulation Testing Product Line	155
9.4.3	Universal Biosensors and Siemens Collaborate on Advanced POC Coagulation Platform	155
9.4.4	Instrumentation Laboratory and Beckman Coulter concluded their Cross-Distribution Agreement	156
9.4.5	CoaguChek® XS Personal Receives Reimbursement Approval for Self-Testing in Japan	156
9.4.6	Diagnostica Stago Launches Products for Measurement of Rivaroxaban	156
9.4.7	Diagnostica Stago Offers Three Factor VII Detection Methods	156
9.4.8	Diagnostica Stago Offers Three Procoagulant Microparticle Detection Methods	157
9.4.9	Diagnostica Stago S.A.S enters into Joint Research Agreement with Bristol-Myers Squibb	157
9.4.10	Trinity Biotech Sold its Worldwide Coagulation Business to the Stago Group	157
9.4.11	Alere aka Inverness Medical Innovations Acquired HemoSense, Inc.	158
9.4.12	Alere Announced Positive Results in Clinical Study Evaluating At-Home Coagulation Testing	158
9.5	Anticoagulation Self-Testing and Self-Management	158
9.6	Market Drivers and Restraints	161
9.6.1	Market Drivers	161
9.6.2	Market Restraints	162
9.7	Impact of New Oral Anticoagulant Drugs on the Coagulation Testing Market	162
9.8	Key Technologies	164
9.9	Key Strategic Recommendations	164
10.	Pathology	165
10.1	Overview	165
10.2	Pathology Markets	165
10.2.1	Market Size	165
10.2.2	Pathology Markets Served	165
10.2.3	Key Technologies	166
10.3	Key Sector Players	166
10.3.1	Ventana Medical Systems Inc. (part of Roche's Diagnostics Division)	166
10.3.2	Dako (An Agilent Technologies Company)	167
10.3.3	Aperio (Part of Leica Biosystems)	167
10.3.4	Abbott Laboratories	167
10.3.5	Omnyx, LLC (Part of GE Healthcare)	168
10.3.6	Visiopharm	168
10.4	Digital Pathology Markets	169
10.4.1	Market Drivers in the Digital Pathology Markets	171
10.4.2	Market Barriers in the Digital Pathology Markets	171
10.4.3	Digital Pathology Takeaways	171
11.	Microbiology	172
11.1	Overview	172
11.1.1	Microbial Culture	172
11.1.2	Biochemical Tests	173
11.2	Microscopy	173
11.3	Microbiology Reagent Market Size and Revenue Analysis	174
11.4	Key Players	175
11.5	Diagnostic Platforms for Infectious Diseases	175
11.5.1	Culture Methods	175
11.5.2	Molecular Diagnostics	175
11.5.3	Mass Spectroscopy	177
11.6	Market Drivers and Restraints in Infectious Disease Testing Markets	178
11.6.1	Market Drivers	178
11.6.2	Market Restraints	178
11.7	Key Sector Takeaways	179
12.	Blood Banking and Screening	180

12.1	Market Overview	180	
12.2	International Markets	180	
12.3	Key Players in Blood Screening	181	
13.	Histology and Cytology Tests	185	
13.1	The Overall Market	185	
13.1.1	Market Size	186	
13.2	Market Drivers	186	
13.3	Market Restraints	186	
13.4	Cytology and Histology Technology Platforms	187	
13.4.1	HLA Typing	187	
13.5	Cytology Screening Procedures and Pap Smear Technology	187	
13.5.1	Cytology	187	
13.5.2	Pap Smears	188	
13.5.2.1	Pap Smear Market Share	191	
13.5.3	Detection of HPV	191	
13.5.3.1	Detection of HPV DNA	191	
13.5.3.2	Benefits of Pap Smear and HPV Co-Testing	192	
13.5.3.3	Human Papillomavirus Testing Market Structure	193	
13.5.3.3.1	HPV Testing Market Overview	193	
13.5.3.3.2	U.S. Market	193	
13.5.3.3.3	European Market	194	
13.5.3.3.4	Latin American Market	195	
13.5.3.3.5	Asian Market	195	
13.6	Histology	196	
13.6.1	IHC Staining	197	
13.6.2	ISH Staining	198	
13.6.3	Special Stains Staining	198	
13.6.4	Tissue Staining Market	198	
13.6.7	Major Players	199	
14.	Data Management and Connectivity	200	
14.1	Wireless LANs	200	
14.2	Connectivity Platforms	202	
14.2.1	DataLink Data Management System	203	
14.2.1.1	DataLink Integrated with RALS®-Plus and Quick Multi-Line	204	
14.2.1.2	DataLink with RALS-Plus	204	
14.2.1.3	DataLink with QML	205	
14.2.2	RALS-Plus, RALS-Web3 and RALS-Freedom	205	
14.2.2.1	International Technidyne Corporation HEMOCHRON Signature Elite	206	
14.2.2.2	Siemens Diagnostics Rapidpoint 500	206	
14.2.2.3	Alere Connect Products	207	
14.2.3	Medical Implant Communications Service (MICS)	207	
14.2.4	Conworx Technology	207	
14.2.5	Alere Informatics	208	
14.2.6	Medasys	208	
14.2.7	NoemaLife	208	
14.3	Advantages of POCT Connectivity	208	
14.3.1	Cost-Benefit Analysis of Testing Devices and IT Connectivity	209	
14.3.2	Hospital Network Issues	209	
14.4	POCT Analyzer Connectivity Software Solutions	210	
15.	Company Profiles	212	
15.1	A. Menarini	212	
15.2	Abaxis, Inc.	212	
15.3	Abbott Laboratories	213	

15.4	Accriva Diagnostics, Inc.	216
15.5	Adaltis	217
15.6	AdnaGen	217
15.7	AdvanDx	217
15.8	Affymetrix, Inc.	218
15.9	Agendia	220
15.10	Agilent Technologies	221
15.11	ALERE, INC.	222
15.12	Alfa Scientific Designs, Inc.	226
15.13	Alfa Wasserman, Inc.	226
15.14	ALPHELYS	227
15.15	AMS	227
15.16	Ambry Genetics	227
15.17	ArcticDx, Inc.	227
15.18	Ariosa Diagnostics, Inc.	228
15.19	ARKRAY USA, Inc.	228
15.20	Asuragen, Inc.	228
15.21	Atlas Genetics	229
15.22	Atonomics A/S	229
15.23	AutoGenomics, Inc.	230
15.24	Awareness Technology	231
15.25	Axxin	232
15.26	Bayer	232
15.27	BD	233
15.28	Beckman Coulter Genomics, Inc.	235
15.29	Biocartis SA	235
15.30	BioCytex	236
15.31	Biodata (Microlink Engineering Systems)	236
15.32	BioData Ltd.	236
15.33	Biodesix	236
15.34	BioGenex Laboratories, Inc.	237
15.35	BioFire Diagnostics, Inc. (Part of bioMérieux now)	237
15.36	BioMedomics	237
15.37	bioMérieux	238
15.38	Biophor Diagnostics	239
15.39	Bio-Rad	240
15.40	Biosensia Ltd.	240
15.41	Biosite Diagnostics (part of Alere)	241
15.42	Biotage AB	242
15.43	bioTheranostics	242
15.44	Cancer Genetics, Inc.	242
15.45	Caris Life Sciences	243
15.46	Cepheid	243
15.47	Celula, Inc.	244
15.48	Chembio Diagnostics, Inc.	244
15.49	Clariant	245
15.50	Coagusense, Inc.	245
15.51	CombiMatrix Corporation	245
15.52	Curetis AG	246
15.53	Cyber Medical Ltd.	246
15.54	Dako A/S (Agilent Technologies)	246
15.55	Debiotech	247
15.56	DexCom	247
15.57	Diagnostica Stago, Inc.	248
15.58	Diagnostica Stago S.A.S	248
15.59	Diagnostics for All	249

15.60	DiaSorin S.p.A.	249
15.61	DxNA, LLC.	249
15.62	Echo Therapeutics	250
15.63	Eiken Chemical Company Limited	251
15.64	Enigma Diagnostics Limited	251
15.65	Epigenomics	251
15.66	Exact Sciences Corporation	252
15.67	Exagen Diagnostics, Inc.	253
15.68	Exiqon	253
15.69	Exosome Diagnostics	253
15.70	FIFTY50 Medical, Inc.	254
15.71	Fluidigm Corporation	254
15.72	Fujirebio Inc.	256
15.73	GE Healthcare	257
15.74	Genera Biosystems	258
15.75	GenMark Diagnostics, Inc.	258
15.76	Genomica S.A.U.	259
15.77	Genomic Health, Inc.	260
15.78	Genomix Biotech	261
15.79	Genoptix, Inc.	261
15.80	Gentag, Inc.	262
15.81	Great Basin Corporation	262
15.82	Grifols	262
15.83	Haemonetics Corporation	262
15.84	Hologic Gen-Probe	263
15.85	Hutman Diagnostics, AG	269
15.86	Hy Laboratories Ltd.	269
15.87	HYPHEN BioMed	270
15.88	Ikonisys Inc.	270
15.89	Illumina, Inc.	270
15.90	Immunexpress Group	273
15.91	Infopia Co., Ltd.	273
15.92	Innovative Biosensors, Inc.	273
15.93	Integrity Applications	273
15.94	InterGenetics, Inc.	274
15.95	Integrated Diagnostics	274
15.96	International Technidyne Corp (THORATEC CORP)	274
15.97	Instrumentation Laboratory	275
15.98	IQuum, Inc.(acquired by Roche)	275
15.99	iSense Corporation (subsidiary of BayerAG)	275
15.100	JEOL Ltd.	275
15.101	Johnson & Johnson	276
15.102	Kommanditgesellschaft Behnk Elektronik GmbH & Co.	277
15.103	Kyowa Medex	277
15.104	LabCorp	277
15.105	Labor BioMedical Technologies GmbH (LABiTec)	278
15.106	Leica Biosystems	278
15.107	Life Technologies Corporation	279
15.108	Luminex Corporation	281
15.109	Lumora Ltd.	285
15.110	M-Biotech	286
15.111	MBio Diagnostics, Inc.	286
15.112	MDxHealth	286
15.113	Medica Corporation, Inc.	286
15.114	Medtronic	287
15.115	Menssana Research, Inc.	288



15.116	Meridian Biosciences	288
15.117	Metaara Medical Technologies Inc.	289
15.118	Miraculins Inc.	289
15.119	Mobidiag	290
15.120	Myriad Genetics, Inc	290
15.121	Nanosphere	298
15.122	Nanostring	299
15.123	Natera Inc.	299
15.124	Neogenomics	300
15.125	Nipro Diagnostics	300
15.126	Nova Biomedical Corporation	300
15.127	Novartis	301
15.128	Novo Nordisk	301
15.129	Nuvera Biosciences	302
15.130	OraSure	303
15.131	Ortho Clinical Diagnostics (Formerly a Johnson & Johnson Company)	304
15.132	Pfizer, Inc.	306
15.133	Phamatech, Inc.	307
15.134	Pharma Supply, Inc.	307
15.135	Polymedco	308
15.136	Prodigy Diabetes Care, LLC (formerly Diagnostic Devices, Inc.)	309
15.137	Qiagen NV	309
15.138	Qidel Corporation	313
15.139	Radiant Pharmaceuticals Corporation	317
15.140	Randox	317
15.141	Roche AG	319
15.142	Rosetta Genomics Ltd.	322
15.143	Sanofi	326
15.144	Seegene	326
15.145	Sekisui Diagnostics	326
15.146	Sensors for Medicine and Science	327
15.147	Sequenom, Inc.	327
15.148	Shimadzu Corporation	328
15.149	Siemens AG	328
15.150	Siemens Healthcare Diagnostics	329
15.151	Sienco Inc.	330
15.152	Simple Diagnostics	330
15.153	SIRS-Lab	330
15.154	Smiths Medical	331
15.155	Source MDx	331
15.156	Spartan Bioscience	332
15.157	Spectrum Laboratories, Inc.	332
15.158	Sysmex America, Inc.	333
15.159	Technoclone GmbH	333
15.160	Telcare	333
15.161	Thermo Fisher Scientific, Inc.	334
15.162	TrimGen	336
15.163	TrovaGene	336
15.164	Trinity Biotech plc	337
15.165	U.S. Diagnostics	337
15.166	Universal Biosensors, Inc.	337
15.167	Ventana	338
15.168	VeraLight	338
15.169	Veredus Laboratories	339
15.170	Veridex (a Johnson & Johnson company)	339
15.171	Visiopharm	340

15.172	Wako	340
15.173	WILEX AG	340
15.174	ZS Genetics	341

## INDEX OF FIGURES

Figure 2.1:	Worldwide Geographic Distribution of Total IVD Testing Market, 2013 and 2018	19
Figure 2.2:	Worldwide Geographic Distribution of Total IVD Testing Markets by Country, 2013	21
Figure 2.3:	Global IVD Market Share by Specialty, 2013	23
Figure 2.4:	Indian Diagnostics Market Segments, 2011	32
Figure 2.5:	Company Market Share for IVD Testing Markets, 2013	37
Figure 3.1:	Percentage Uptake by Analyte in Hospitals Performing POC Testing	46
Figure 3.2:	Total Global POCT Market, 2008-2018	47
Figure 3.3:	Worldwide Distribution of POCT, 2013	48
Figure 3.4:	Summary of Global POCT Markets by Market Segment, 2013	49
Figure 4.1:	Global Market for Molecular Diagnostics, 2002-2019	57
Figure 4.2:	Market Share by Region for Molecular Diagnostics Testing, 2013	58
Figure 4.3:	Key Players Market Share in Global Molecular Diagnostics Testing Markets, 2013	59
Figure 4.4:	Share of Molecular Diagnostics Testing by Application, 2013	60
Figure 4.5:	Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018	61
Figure 4.6:	Total Global Infectious Disease Molecular Diagnostics Markets, 2013	64
Figure 4.7:	Key Players Market Share in Global Molecular Diagnostics Cancer Testing Markets	67
Figure 4.8:	Molecular Diagnostic Markets for Cancer Testing Globally, 2013	73
Figure 4.9:	Molecular Diagnostic Markets for Cancer Testing U.S., 2013	73
Figure 5.1:	Global Clinical Chemistry Revenues, 2000-2018	94
Figure 5.2:	Worldwide Geographical Distribution of Clinical Chemistry Testing, 2013	95
Figure 6.1:	Geographic Segments of the Worldwide Glucose Self-Testing Market, 2012 and 2018	113
Figure 6.2:	Worldwide Glucose Self-Testing Market by Region, 2018	113
Figure 6.3:	Personal Lancet Unit Sales Market Share by Geographic Region, 2013	122
Figure 7.1:	Market Share for Key Players in Immunoassay Testing Markets, 2013	127
Figure 9.1:	Global Revenue Forecasts for Coagulation Testing, 2010-2018	150
Figure 9.2:	U.S. Revenue Forecasts for Coagulation Testing, 2010-2018	150
Figure 9.3:	European Revenue Forecasts for Coagulation Testing, 2010-2018	151
Figure 9.4:	Japanese Revenue Forecasts for Coagulation Testing, 2010-2018	152
Figure 9.5:	ROW Revenue Forecasts for Coagulation Testing, 2010-2018	152
Figure 10.1:	Market Shares in Pathology Diagnostics, by Company	166
Figure 10.2:	The Global Laboratory Digital Pathology Market, 2012-2018	170
Figure 13.1:	Liquid-Based Pap Test Market Share	191
Figure 14.1:	The RALS Data Management System Connects to Most of the Major Instruments Used in Point of Care	204
Figure 14.2:	AegisPOC Point of Care and Critical Care Connectivity and Information Management System	210

## INDEX OF TABLES

Table 2.1:	Global Distribution of IVD Testing by Key Geographic Regions, 2013 and 2018	19
Table 2.2:	Global GDP Growth Rates, 2011 to 2015	20
Table 2.3:	Top 15 Country Markets for IVD Testing, 2013	22
Table 2.4:	Global Distribution of IVD Testing by Market Segments, 2013-2018	23
Table 2.5:	Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018	24
Table 2.6:	Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018	25
Table 2.7:	Summary of IVD High-Growth Market U.S., 2013	25
Table 2.8:	Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., 2008-2018	26
Table 2.9:	U.S. Individual IVD High-Growth Markets Revenue Forecast 2008-2018	26
Table 2.10:	Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	28

Table 2.11: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Asia, 2008-2018	28
Table 2.12: Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	29
Table 2.13: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018	29
Table 2.14: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	30
Table 2.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018	30
Table 2.16: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	31
Table 2.17: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018	33
Table 2.18: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	34
Table 2.19: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018	36
Table 2.20: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	36
Table 2.21: Company Market Share for IVD Testing Markets, 2013	37
Table 2.22: Market Trends in the Diagnostics Space	38
Table 3.1: Summary of Global POCT Markets by Major Market Sub-Segment, 2013 and 2018	50
Table 3.2: Global Company Market Share POCT Analysis, 2013	50
Table 3.3: Main Drivers for the Point of Care Market	53
Table 4.1: Applications of Molecular Diagnostics Technology Platforms	56
Table 4.2: Global Distribution of Molecular Diagnostics Testing by Geographic Region, 2013	57
Table 4.3: Key Players and Market Share in the Global Molecular Diagnostics Testing Market, 2013	59
Table 4.4: Share of Molecular Diagnostics Testing by Application, 2013	60
Table 4.5: Future Areas of Growth in Molecular Diagnostics	60
Table 4.6: Molecular Diagnostics Infectious Disease Market Drivers Ranked in Order of Impact	63
Table 4.7: Molecular Diagnostics Infectious Disease Market Restraints Ranked in Order of Impact	63
Table 4.8: Molecular Diagnostics Infectious Disease Sector: Strategic Recommendations on Business Functions	63
Table 4.9: Nucleic Acid Testing Reagents for HIV Testing	65
Table 4.10: Nucleic Acid Testing Reagents for HBV Testing	65
Table 4.11: Nucleic Acid Testing Reagents for HCV Testing	65
Table 4.12: Molecular Diagnostic Markets for Cancer Testing, 2012	66
Table 4.13: Specific Diagnostic Products Categories Comprising the General Cancer Diagnostic Market	71
Table 4.14: Highlights of the Cancer Molecular Diagnostic Testing Segment	71
Table 4.15: Highlights of Certified Clinical Labs Specializing in Cancer Genetics and Molecular Diagnostic Services	71
Table 4.16: U.S. Market for Molecular Diagnostics Cancer Testing, 2008-2018	72
Table 4.17: Key Diagnostic Company Players and Market Share in Global Molecular Diagnostics Cancer Testing Market	74
Table 4.18: Key Players in the Breast Cancer Molecular Diagnostic Space	74
Table 4.19: Commercially Available Molecular Diagnostic Products for Breast Cancer Assay	75
Table 4.20: Oncotype DX Overview	77
Table 4.21: Comparison of Agendia vs. Genomic Health Breast Cancer Tests	77
Table 4.22: Clariant's Offerings in Breast Cancer Testing	78
Table 4.23: Trends in Cancer Personalized Medicine	84
Table 4.24: Commercial Labs Performing Genetic Testing	86
Table 4.25: Technology Trends in Cancer Testing	89
Table 4.26: Trends in Theranostics	90
Table 4.27: Market Trends in Cancer Testing	90
Table 4.28: Molecular Diagnostics Cancer Market Drivers Ranked in Order of Impact	91
Table 4.29: Molecular Diagnostics Cancer Market Restraints Ranked in Order of Impact	91
Table 5.1: Global Distribution of General Chemistry Testing by Geographic Region, 2013-2018	95
Table 5.2: Leading Marketeters of Automated Clinical Chemistry Instruments	97
Table 5.3: Ultra-Large Clinical Chemistry Analyzers	99
Table 5.4: Large Clinical Chemistry Analyzers	101

Table 5.5: Mid-Size Clinical Chemistry Analyzers	102
Table 5.6: Small Clinical Laboratory Analyzers	103
Table 5.7: Clinical Chemistry Analyzer Market Drivers Ranked in Order of Impact	105
Table 5.8: Clinical Chemistry Analyzer Market Restraints Ranked in Order of Impact	106
Table 6.1: Worldwide Comprehensive Glucose Testing Market (Includes Reagents and Supplies in both the Self-Testing and Professional Markets in \$ Billions), 2012-2018	110
Table 6.2: Global Revenues for Total Professional Blood Glucose Monitoring (Central Laboratory Testing and Hospital POC and POL), 2012-2018	111
Table 6.3: Global Revenues for Professional Point of Care Blood Glucose Monitoring Systems (within Hospitals and Physician's Offices), 2012-2018	111
Table 6.4: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, and Lancets), 2012-2018	112
Table 6.5: Revenues and Market Shares in the SMBG Market in 2013, by Company	114
Table 6.6: Unit Sales of Homecare Lancets in the U.S., 2012-2017	118
Table 6.7: Unit Sales of Homecare Lancets in the E.U., 2012-2017	118
Table 6.8: Dollar Sales of Homecare Lancets in the U.S., 2012-2017	119
Table 6.9: Dollar Sales of Homecare Lancets in the E.U., 2012-2017	119
Table 6.10: Unit Sales of Homecare Glucose Self-Testing Lancets in the U.S., 2012-2017	119
Table 6.11: Unit Sales of Homecare Glucose Self-Testing Lancets in the E.U., 2012-2017	119
Table 6.12: Competition in the Lancet Market Segment	121
Table 7.1: Global Revenue Forecasts for Immunoanalyzer Testing, 2012-2018	126
Table 7.2: Immunoanalyzer Market Drivers Ranked in Order of Impact	135
Table 7.3: Immunoanalyzer Market Restraints Ranked in Order of Impact	135
Table 8.1: Global Clinical Hematology Analyzer and Reagent Revenues, 2008-2018	142
Table 8.2: Worldwide Distribution of Clinical Hematology Testing Analyzer and Reagent Revenues, 2013	143
Table 8.3 Key Players in Worldwide Hematology Analyzers and Reagent Market	144
Table 8.4: Hematology Analyzers Currently in Market, 2014	146
Table 9.1: Key Players in Anticoagulation Sector	153
Table 9.2: Benefits of Anticoagulation Self-Testing	158
Table 9.3: Barriers to Anticoagulation Self-Testing and Self-Management	160
Table 9.4: Key Market Drivers for Coagulation Testing	162
Table 9.5 Market Drivers for Point of Care Anticoagulation Testing Market	162
Table 9.6 Key Market Restraints for Coagulation Testing	162
Table 9.7: Market Restraints for Point of Care Anticoagulation Testing Market	162
Table 10.1: Global Distribution of Pathology Equipment and Reagents by Geographic Region, 2013-2018	165
Table 10.2: Anatomical Laboratory Computer Systems Manufactures	169
Table 10.3: Digital Pathology Market Drivers Ranked in Order of Impact	171
Table 10.4: Digital Pathology Market Restraints Ranked in Order of Impact	171
Table 11.1: Global Microbiology Reagent Sales 2013-2018	175
Table 11.2: Clinical Microbiology Market Drivers Ranked in Order of Impact	178
Table 11.3: Clinical Microbiology Market Restraints Ranked in Order of Impact	178
Table 12.1: Global Distribution of Blood Banking Reagents Sales by Geographic Region, 2013-2018	180
Table 12.2: Key Players in Blood Banking and Transfusion Markets	181
Table 12.3: Roche's cobas s 201 system: Competitive Advantages	183
Table 12.4: Blood Bank information Systems	184
Table 13.1: Global Histology and Cytology Sales by Segment, 2013-2018	185
Table 13.2: Cytology and Histology Market Drivers Ranked in Order of Impact	186
Table 13.3: Cytology and Histology Market Restraints Ranked in Order of Impact	187
Table 13.4: Estimated Number of Pap Smears Performed by Country, 2013	189
Table 13.5: Global Market for HPV Molecular Diagnostic Testing, 2009-2017	193
Table 13.6: U.S. Market for HPV Diagnostic Testing, 2009-2017	194
Table 13.7: Tissue Diagnostics Market Segments	199
Table 14.1: Applications for Wireless LAN Technology	200
Table 14.2: Customized Reports Must Support CAP and JCAHO Requirements	203
Table 14.3: Applications of RALS Connectivity with POCT Devices	205
Table 15.1: Drugs of Abuse Cut-off Levels for the TOX/See Test by Bio-Rad	240
Table 15.2: OraSure Portfolio of Drugs of Abuse Detection Methodologies	304

## 1. IVD Market Overview

### 1.1 Statement of Report

*In vitro* diagnostic (IVD) testing is experiencing a revival fueled by a combination of technological improvements, cost pressures, reimbursement changes, rapid growth in molecular diagnostics and increasing interest in the genomics testing. Recent advances in molecular diagnostics technologies—including sequencing, PCR and microarrays—are enabling greater sensitivity and precision in nucleic acid measurements, further expanding manufacturers' offerings. This TriMark Publications report is an overview of each major *in vitro* diagnostic testing segment, including: point-of-care testing (POCT), molecular diagnostics, chemistry, diabetes and glucose, immunoassay, hematology, coagulation, pathology, microbiology, histology and cytology, and blood banking. For each segment, this study examines the generally accepted clinical analytical activities in use today. Moreover, the analysis here discusses the potential benefits of the diagnostics techniques, as well as provides market size and future growth potential. Additionally, this report assesses the various business models, including CLIA-licensed specialty labs, general reference labs and reagent kit marketing. This study also examines hundreds of companies that are actively developing and marketing IVD testing products around the world. This report analyzes the size and growth of the important sectors of the diagnostics market, including the drivers and restraints that influence the various market segments, as well as the dollar volume of sales and market growth rates, both in the U.S. and worldwide.

### 1.2 About This Report

This report includes the following features for each major IVD market segment:

- It examines the generally accepted clinical analytical activities in use today in the diagnostics (IVD) sector for diagnosis and management of disease. It includes the prevalent clinical-measurement devices and the accompanying reagents and supplies as utilized in hospitals and large reference and specialty Clinical Laboratory Improvements Act (CLIA) licensed laboratories, as well as physicians' offices and point of care testing.
- It discusses the potential benefits of the diagnostics techniques for various sectors of the medical and scientific communities in serving patients and managing disease, and it assesses the market drivers and bottlenecks for IVD tests from the perspective of these communities.
- It establishes the current total IVD market size and future growth of the diagnostics market for disease management, and analyzes the current size and growth of key segments.
- It assesses various business models in diagnostics, including CLIA-licensed specialty labs, general reference labs and reagent kit marketing and provides strategic recommendations for near-term business opportunities.
- It examines the roles played by companies that have invested significantly in this market, and it provides current and forecasted market shares by these companies.

### 1.3 Scope of the Report

The goal of this study is to review the market for IVD diagnostics testing equipment and supplies using reagents and instruments for analysis of individual components in body tissues and fluids. Toward this goal, this review:

- Identifies the major segments in IVD markets.
- Estimates the current and future U.S. and global markets for *in vitro* diagnostics for various disease sectors.
- Examines market drivers that have resulted in the global race for new *in vitro* diagnostics.
- Reviews the impact of current products and the future of the diagnostics industry.
- Provides insight into the diagnostics products in the pipeline and the companies that strive to bring these products to the market in the immediate future.

- Evaluates global activity of IVD with specific contributions from the top-ranking five country markets: U.S., Japan, Europe, China and ROW.

Key questions answered in this study are:

- What products are included in the phrase “*in vitro* diagnostics”?
- What disease conditions offer the greatest potential for diagnostics technology platforms?
- What is the current global market for *in vitro* diagnostics?
- What regulatory and technical challenges are being confronted by the diagnostics industry?
- What are the current promising developments in each major diagnostics sector?

This examination surveys most of the biotech companies known to be currently marketing, manufacturing or developing instruments and reagents for the diagnostics market for disease diagnosis and management, in both the U.S. and the world. Each company is discussed in depth, with sections on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position. Market size, growth rates and market components for instruments, reagents, controls and consumables used in this area are also analyzed.

#### 1.4 Objectives

The reader should consult other TriMark Publications reports for detailed discussions of important individual market segments related to the molecular diagnostics market or routine testing. In addition to this report, TriMark Publications offers a complete suite of market reports aimed at the molecular diagnostic space including: *Molecular Diagnostics Markets*, *Molecular Diagnostics in Infectious Disease Testing*, *Molecular Diagnostics in Cancer Testing* and *Molecular Diagnostics in Genetic Testing*.

#### 1.5 Methodology

The principal author of this report holds a Ph.D. in biochemistry from the University of Minnesota, and had his post-doctoral studies at the University Of Connecticut School of Medicine. He has taught at Quinnipiac University, the Tufts School of Medicine and New York Institute of Technology. He has been a senior scientist at DuPont and Pfizer Pharmaceutical Laboratories in drug development and diagnostic testing. He was a leader in the formation and development of Dianon Laboratories, now part of LabCorp. He also has many decades of experience in science writing and as a medical industry analyst and consultant. He has over 40 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies. The editor holds a Ph.D. in life sciences from Jawaharlal Nehru University, with post-doctoral training from the University of Manitoba and Saskatoon Cancer Centre, respectively. She has authored several peer-reviewed articles on signaling pathways involved in cancer progression, and has over six years’ experience as a scientific editor.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates’ databases and from TriMark’s private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

### ***Primary Sources***

TriMark collects information from full market reports, hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

### ***Secondary Sources***

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

### ***TriMark Publications Report, Research and Data Acquisition Structure***

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
  - Market and product segment grouping, and evaluating their relative significance.
  - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
  - Supply chain research and analysis to identify any factors affecting the market.
  - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

For projection for the future values and growth rates of specific markets our analysts use a proprietary forecast spreadsheet, which takes into account a wide variety of market indices such as inflation rates and anticipated increases and decreases in funding of specific markets. Then, other factors such as new market introductions, acquisitions, and other factors are manually incorporated into the spreadsheet.

## **1.6 Executive Summary**

The total IVD market was \$ [REDACTED] in [REDACTED]. Growing at a CAGR of [REDACTED]%, it is on track to reach \$ [REDACTED] by [REDACTED]. North America accounted for an estimated [REDACTED]% of the IVD testing hospital market in [REDACTED], Europe for [REDACTED]%, Asia Pacific for [REDACTED]% and the rest of the world for [REDACTED]%. Total IVD revenues are growing at a rate of [REDACTED]% to [REDACTED]% per year worldwide, The U.S. and Western Europe are the largest IVD markets. Asia Pacific and Eastern Europe are projected to be the fastest growing. Revenue for the global the IVD market is forecasted to reach \$ [REDACTED] by [REDACTED].

The Asia Pacific area, which is led by the Chinese and Indian national markets (once Japan is excluded), is expected to be the fastest growing region for IVD market applications during the period [REDACTED] to [REDACTED] with a CAGR of [REDACTED]%. The market for IVD testing in Asia (including Japan) is estimated to be \$ [REDACTED] in [REDACTED]. The Asia Pacific region will account for [REDACTED]% of the world IVD market by [REDACTED]. IVD sales in China have grown more than [REDACTED]% per year for the past four to five years and now stand at more than \$ [REDACTED]. The IVD markets of China and India, two countries that account for approximately one-third of the world's population, have demonstrated remarkable growth in the past decade. The IVD markets in these two countries have seen steady growth rates of [REDACTED]% to [REDACTED]% per year over the past [REDACTED] years.

TriMark estimates that the global POCT market was valued at \$ [REDACTED] in [REDACTED], equivalent to [REDACTED]% of the global IVD market. It is estimated that the global POCT market will exhibit a compound annual growth rate (CAGR) of [REDACTED]% between [REDACTED] and [REDACTED] to \$ [REDACTED]. Within the POCT markets, glucose testing remains the leading global segment, projected to account for [REDACTED]% of global near-patient testing by [REDACTED]. Excluding glucose testing, in the point-of-care (near-patient) segment, only rapid cardiac markers rises above \$ [REDACTED] in POCT testing by [REDACTED], accounting for an estimated [REDACTED]% of total testing by [REDACTED]. TriMark is publishing a report with more detail called *Point of Care Diagnostic Testing World Markets*.

Worldwide, approximately \$ [REDACTED] was spent on molecular diagnostics tools, assays and other products in [REDACTED], corresponding to a CAGR of more than [REDACTED]%. The CAGR is projected to be around [REDACTED]% through [REDACTED], reaching \$ [REDACTED] by that year. Of this amount, approximately [REDACTED]% was spent on assays used for testing infectious diseases. The remaining [REDACTED]% was spent for other products, such as those used in cancer markers and genetic testing.

A summary review of the global IVD high-growth markets as a percentage of revenues by geographic region is provided in the next table in the form of a five-year revenue forecast. Whilst the U.S. will obtain a higher proportion of the global market between [REDACTED] and [REDACTED], it is expected that it will decline between [REDACTED] and [REDACTED]. It is anticipated that this will be as a direct result of the increase share of the global market by the emerging markets and, in particular, the effect of the increase in the market for IVD products in the BRIC countries. The value of the IVD high-growth diagnostic testing market in the U.S. in [REDACTED] was \$ [REDACTED]. By the end of the forecast period in [REDACTED], it is predicted that the market will have increased in value to \$ [REDACTED] (CAGR [REDACTED]%). TriMark is publishing a report with more detail called *High-Growth Diagnostic Testing Markets*.

Many of the new high-growth IVD products and services are specifically targeted at markets outside of the traditional hospital or clinical laboratory such as the point of care setting or genetic screening. Competition in the development and marketing of high-growth diagnostic products is intense, and diagnostic technologies have been subject to rapid change. TriMark estimates that the competitive factors determining success in the diagnostic market include convenience, privacy, price and product performance as well as the distribution, advertising, promotion and brand name recognition of the marketer.

As more and more targeted drugs come onto the market in the next decade, there will be a growing need for diagnostics that can help predict and match patients with drugs which will serve them best. With a broad portfolio of genetic and proteomic analysis platforms, large diagnostic companies will be able to give a pharmaceutical company a flexible, cost-effective means to manage the evolution of the companion diagnostic assay through the drug development process. Leading clinical diagnostics companies, with the tools and technologies to help define the future of patient care, are looking forward to opportunities for collaborating with pharmaceutical companies and extending their position in specialty areas to take advantage of opportunities, particularly for early disease diagnosis and improved treatment regimens in the emerging companion diagnostic market.

Over the past few years, there has been a dramatic shift in diagnostic testing which is steadily moving away from the centralized laboratory setting to the operating room, bedside, clinic and home points of care. Factors such as rapid technological advancements, expanded test menus, user-friendly instrumentation, and improved connectivity and data management, are the main drivers of growth in the IVD markets. IVD in near-patient settings serve to improve patient outcomes and lower overall healthcare costs by reducing diagnosis times, resulting in shorter timeframes to therapeutic intervention. Accelerated adoption of POCT devices is evident in the global shift toward POCT from centralized laboratory testing. Forces shaping the landscape include evolution of innovative technologies, an aging population, increased incidence of chronic disease such as diabetes, development of personalized medicine and promising new opportunities in emerging markets.



The major drivers of the IVD markets include molecular methodologies such as nucleic acid amplification (in particular PCR), sequencing, microarrays and *in situ* hybridization (ISH). IVD manufacturers are constantly improving on and expanding their product offerings to keep pace with ever-evolving end-user needs. While major players in the IVD industry attempt to increase market share by intensifying product development efforts in POCT—for example, Abbott and Alere—the industry remains highly fragmented, and there is room for smaller players to enter and compete with innovative platforms and expansive test menus. As the IVD markets continue to grow and evolve—shaped by growing demand for IVD products and services—the industry is also experiencing escalating deal activity in many sectors. Within these rapidly growing areas of the diagnostics market, strategic acquisitions allow companies to expand existing portfolios with complementary products and capabilities.

#### Market drivers:

- Tests based upon molecular diagnostic (nucleic acid) technology platforms.
- Move toward marketing rapid point of care test kits.
- Tests developed as CLIA-waived tests.
- Cost per test less of an issue with high demand diagnostic tests.
- Coupling the diagnostic test with high profile diseases, *e.g.*, ovarian or breast cancer.
- Move toward bringing complicated tests into a single expert lab.
- Move for CLIA regulatory oversight using expert labs, rather than FDA using diagnostic kits.
- Move away from central lab “big iron” chemistry analyzers.
- Focus on improving patient outcomes with diagnostic tests using so called personalized medicine.
- Move to reduce expertise needed to run tests because of shortage of trained personnel.
- More diagnostic start-ups to develop tests with high growth potential.
- Increased M&As as larger players acquire exciting new test technology.
- Improving profit margins through improved product pricing and operational efficiencies.
- Securing a stronger new product pipeline from internal research and development.
- Pursuing licensing and acquisitions opportunities, when financially and strategically attractive.
- Launching diagnostic test business under a brand by leveraging marketing and distributing strength in the U.S., maximizing worldwide sales through current and newly identified sales channels in Europe and the rest of world.
- Launching a new and improved CLIA-waived test worldwide.
- Launching rapid diagnostic tests on a worldwide basis in conjunction with a development partner such as a pharmaceutical company, *i.e.*, companion diagnostic testing.
- Expanding development and marketing collaborations with large pharmaceutical and other healthcare companies.
- Identifying business development opportunities in the form of product or company acquisitions to enhance product portfolio and further leverage distribution channels worldwide.
- Expanding international sales through external alliances, collaborations and sales focus.
- Consolidation remains an attractive option in the IVD industry, which has been experiencing high rates of M&A activity over the past few years, and TriMark expects this trend to continue.